A randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI

Background Ischemia-reperfusion injury remains a major clinical problem in patients with ST-elevation myocardial infarction (STEMI), leading to myocardial damage despite early reperfusion by primary percutaneous coronary intervention (PPCI). There are no effective therapies to limit ischemia-reperfu...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar:	Adlam, D, Zarebinski, M, Uren, NG, Ptaszynski, P, Oldroyd, KG, Munir, S, Zaman, A, Contractor, H, Kiss, RG, Édes, I, Szachniewicz, J, Nagy, GG, Garcia, MJ, Tomcsanyi, J, Irving, J, Sharp, ASP, Musialek, P, Lupkovics, G, Shirodaria, C, Selvanayagam, JB, Quinn, P, Ng, L, Roth, M, Insko, MA, Haber, B, Hill, S, Siegel, L, Tulloch, S, Channon, KM
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Elsevier 2021

A randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI

Benzer Materyaller